ArticleInternational journal of molecular sciences2015
CXCL13 promotes the effect of bone marrow mesenchymal stem cells (MSCs) on tendon-bone healing in rats and in C3HIOT1/2 cells.
Article in International journal of molecular sciences, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 26 citations in OpenAlex.
- Mechanotransduction unifies healthy nondiabetic wound healing over time by promoting a Cd14+/C1qa+ fibroblast subpopulation.The Journal of investigative dermatology · 2026Article
- Post-myocardial Infarction Cardiac Remodeling: Multidimensional Mechanisms and Clinical Prospects of Stem Cell Therapy.Stem cell reviews and reports · 2025Review
- Correlation of serum and local CXCL13 levels with disease severity in patients with non-traumatic osteonecrosis of femoral head.Journal of orthopaedic surgery and research · 2024Article
- Characterization of C-X-C chemokine receptor type 5 in the cornea and role in the inflammatory response after corneal injury.Experimental eye research · 2023Article
- Strategies for promoting tendon-bone healing: Current status and prospects.Frontiers in bioengineering and biotechnology · 2023Review
- Strategies to promote tendon-bone healing after anterior cruciate ligament reconstruction: Present and future.Frontiers in bioengineering and biotechnology · 2023Review
- Roles of MicroRNAs in Osteogenesis or Adipogenesis Differentiation of Bone Marrow Stromal Progenitor Cells.International journal of molecular sciences · 2021Review
- WNT5A inhibition alters the malignant peripheral nerve sheath tumor microenvironment and enhances tumor growth.Oncogene · 2021Article
- Basic Research on Tendon Repair: Strategies, Evaluation, and Development.Frontiers in medicine · 2021Review
- Cytokine Consistency Between Bone Marrow and Peripheral Blood in Patients With Philadelphia-Negative Myeloproliferative Neoplasms.Frontiers in medicine · 2021Article
- The transition of M-CSF-derived human macrophages to a growth-promoting phenotype.Blood advances · 2020Article
- Deficiency of the SMOC2 matricellular protein impairs bone healing and produces age-dependent bone loss.Scientific reports · 2020Article
- Current trends in tendinopathy: consensus of the ESSKA basic science committee. Part II: treatment options.Journal of experimental orthopaedics · 2018Review
- Baicalein Accelerates Tendon-Bone Healing via Activation of Wnt/BioMed research international · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesMesenchymal stem cells (MSCs) are potential effective therapy for tissue repair and bone regeneration. In present study, the effects of CXC chemokine ligand-13 (CXCL13) were evaluated on tendon-bone healing of rats.
methodsTendon bone healing of the rat model was established and biomechanical testing was performed at 2, 4, 8 weeks after surgery. Murine mesenchymal cell line (C3HIOT1/2 cells) was cultured. The expression of miRNA-23a was detected by real-time PCR. The protein expression of ERK1/2, JNK and p38 was detected by western blotting. MiR-23a mimic and inhibitor were used to overexpress or silence the expression of miR-23a.
resultsMSCs significantly elevated the levels of ultimate load to failure, stiffness and stress in specimens of rats, the effects of which were enhanced by CXCL13. The expression of miR-23a was down-regulated and the protein of ERK1/2 level was up-regulated by CXCL13 treatment in both in vivo and in vitro experiments. ERK1/2 expression was elevated by overexpression of miR-23a and reduced by miR-23a inhibitor.
conclusionsThese findings revealed that CXCL13 promoted the tendon-bone healing in rats with MSCs treatment, and implied that the activation of ERK1/2 via miR-23a was involved in the process of MSCs treated bone regeneration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.